Shots:
- Ensoma to receive $100M in up front & preclinical research payment, $10M in equity investment, and is eligible to receive $1.25B as development and commercialization milestones along with royalties on sales of each product
- Takeda to get an exclusive WW rights Ensoma’s Engenious vectors for up to five rare disease indications. Ensoma to conduct preclinical research activities for the Takeda programs, and both parties will share in responsibilities leading to submission of IND applications. Takeda will lead development activities thereafter
- Additionally, Ensoma launches to next-generation in vivo approach to deliver first “off-the-shelf” genomic medicines with the $70M series A funding
Click here to read full press release/ article | Ref: Businesswire | Image: Businesswire
The post Takeda Collaborates with Ensoma to Accelerate Next-Generation In Vivo Gene Therapies first appeared on PharmaShots.
